01.03.2010 • NewsCatalysis & CatalystsEvonikH.C. Starck

Evonik Acquires Catalyst Business From H.C. Starck

Evonik Industries has acquired the catalyst business of H.C. Starck GmbH based in Goslar, Germany. The know-how and technology relating to the production and use of Amperkat catalysts have therefore been transferred to Evonik. Following a transition phase, Evonik will produce these catalysts in Hanau, Germany. The Amperkat brand comprises activated metal catalysts-known as skeletal catalysts and customized supported catalysts. The Amperkat business focuses principally on activated nickel catalysts, which are used in the pharmaceuticals and food industries and in fine and industrial chemicals, for example, for producing selective pharmaceutical active substances, sweeteners, and starting materials for polyurethanes for the building materials and automotive sectors.

Evonik is a global leader in producing activated metal catalysts and precious metal powder catalysts. Both product groups are used in similar market segments, but their activity and selectivity differ enormously. The acquisition of Amperkat catalysts complements Evonik's present range of products and customized solutions.

 

Company

Logo:

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read